Navigation Links
Study identifies double-balloon enteroscopy as cost-effective approach for obscure GI bleeding
Date:11/24/2008

University Hospital, Calif. "We performed a decision analysis to explore the optimal management strategy for patients with obscure GI bleeding and found that among the current options for diagnosis and management of small bowel lesions, an initial double-balloon enteroscopy would be a cost-effective approach because of its ability to identify and treat lesions during the initial small bowel examination."

Patients and Methods

The study did not use an actual patient, but rather a model that played out different possible treatment options. The base-case (hypothetical) patient was a 50-year-old man with a six-month history of recurrent melena (stools stained black by blood pigment or dark blood products) and associated iron deficiency. The patient had a prior normal upper endoscopic examination, colonoscopy, and small bowel x-ray series. The patient was considered to be a candidate for a CE, as well as endoscopic or surgical therapy, for presumed small-bowel sources of the bleeding.

A cost-effectiveness analysis is a quantitative method used to evaluate the outcomes and costs of interventions designed to improve health. Researchers in this study used decision analysis software to create a decision flow chart to compare no therapy (reference arm) to five other treatment options: (1) push enteroscopy, (2) intraoperative enteroscopy (done in an operating room requiring a formal surgery), (3) angiography, (4) initial anterograde DBE, followed by a retrograde DBE if the patient had ongoing bleeding, and (5) small bowel CE followed by a DBE guided by the CE findings. Patients in the CE arm would only proceed to a DBE if they had persistent obscure bleeding after the CE examination. Patients with normal CE examinations and ongoing GI hemorrhage would undergo an initial anterograde DBE, with the assumption that a lesion might have been missed on the prior CE examination. The patients in the no-therapy arm would not undergo any endoscopic intervent
'/>"/>

Contact: Anne Brownsey
abrownsey@asge.org
630-570-5635
American Society for Gastrointestinal Endoscopy
Source:Eurekalert

Page: 1 2 3 4 5

Related medicine news :

1. Health study in northern Uganda calls for improved services for internally displaced persons
2. Pregnancy study finds strong association between two antidepressants and heart anomalies
3. Wide-Ranging Study of National News Reveals Health News Comprises Less Than Four Percent of All Coverage
4. Study of ancient and modern plagues finds common features
5. Physicians Anticipate Higher Prescribing Based on JUPITER Study
6. New Study Data: JANUVIA™ (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes
7. STAAR Surgical Forms Team of Leading Ophthalmic Surgeons to Study the Use of Collamer(R) Material for Accommodating Intraocular Lenses
8. Landmark study defines benefits of early HIV testing and treatment for infected infants
9. Study identifies causes of bone loss in breast cancer survivors
10. New Study by BioTrends Highlights Practice Management Shifts Among Canadian Nephrologists
11. Study Suggests Need for More Aggressive Outpatient Monitoring of Patients Hearts When Cause of Stroke is Unclear
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Innovative Applications of Flow Cytometry Win U.S. and European Researchers Free Accuri C6 Flow Cytometer(R) Systems 2Health News:Innovative Applications of Flow Cytometry Win U.S. and European Researchers Free Accuri C6 Flow Cytometer(R) Systems 3Health News:Innovative Applications of Flow Cytometry Win U.S. and European Researchers Free Accuri C6 Flow Cytometer(R) Systems 4Health News:InfoZoom Launches V6.4 of its Industry Leading In-Memory Data Analysis Software 2Health News:InfoZoom Launches V6.4 of its Industry Leading In-Memory Data Analysis Software 3Health News:Frost & Sullivan: E-Healthcare in Western Europe Presents a Significant Market Opportunity for Wireless Technologies 2Health News:Frost & Sullivan: E-Healthcare in Western Europe Presents a Significant Market Opportunity for Wireless Technologies 3Health News:REES Announces New Baltimore Office 2Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 2Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 3Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 4Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 5Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 6
Breaking Medicine Technology:Royalty Pharma Announces that Alexander von Perfall Joins Management Team 2Hill-Rom Announces Appointment of James R. Giertz to Board of Directors 2Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 2Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 37 Proven Steps 3A How to Defeat Stress Without Going Through the Embarrassment of Counseling 3A Proven Ways to Defeat Stress 49176 17 Proven Steps 3A How to Defeat Stress Without Going Through the Embarrassment of Counseling 3A Proven Ways to Defeat Stress 49176 27 Proven Steps 3A How to Defeat Stress Without Going Through the Embarrassment of Counseling 3A Proven Ways to Defeat Stress 49176 3iMedica Selected by NJ Physicians as Preferred EHR Vendor 49173 1iMedica Selected by NJ Physicians as Preferred EHR Vendor 49173 2Somanetics Reports Second Quarter Results and Extension of Exclusive Distribution Agreement With Covidien 49170 1Somanetics Reports Second Quarter Results and Extension of Exclusive Distribution Agreement With Covidien 49170 2Somanetics Reports Second Quarter Results and Extension of Exclusive Distribution Agreement With Covidien 49170 3Somanetics Reports Second Quarter Results and Extension of Exclusive Distribution Agreement With Covidien 49170 4Somanetics Reports Second Quarter Results and Extension of Exclusive Distribution Agreement With Covidien 49170 5Somanetics Reports Second Quarter Results and Extension of Exclusive Distribution Agreement With Covidien 49170 6Somanetics Reports Second Quarter Results and Extension of Exclusive Distribution Agreement With Covidien 49170 7Somanetics Reports Second Quarter Results and Extension of Exclusive Distribution Agreement With Covidien 49170 8Somanetics Reports Second Quarter Results and Extension of Exclusive Distribution Agreement With Covidien 49170 9Somanetics Reports Second Quarter Results and Extension of Exclusive Distribution Agreement With Covidien 49170 10